MT106 / Medytox - LARVOL DELTA

Medytox's blood cancer treatment candidate wins government support (Korea Biomedical Review) - "Medytox said that the Korea Drug Development Fund (KDDF) has selected Bruton's tyrosine kinase (BTK) inhibitor-based anticancer drug MT106 development project as a new national drug development project. The national new drug development project is a cross-ministerial R&D project established to secure global competitiveness in the local drug development field. Accordingly, Medytox will receive administrative and financial support for R&D expenses necessary to derive candidate substances for the next 24 months from the KDDF."

Grant • Oncology